Yuan Qing Sarah 4
4 · Sigilon Therapeutics, Inc. · Filed Aug 11, 2023
Insider Transaction Report
Form 4
Yuan Qing Sarah
CTOO
Transactions
- Disposition to Issuer
Common Stock
2023-08-11−2,884→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-11$0.75/sh−8,846$6,635→ 0 totalExercise: $14.17Exp: 2033-02-27→ Common Stock (8,846 underlying)
Footnotes (3)
- [F1]Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right ("CVR") per share.
- [F2]Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
- [F3]Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time.